About the Authors
Wellcome Trust-Mahosot Hospital-Oxford Tropical Medicine Research Collaboration, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
WorldWide Antimalarial Resistance Network (WWARN), University of Oxford, Oxford, United Kingdom
Malaria & Child Survival Department, Population Services International, Nairobi, Kenya
Wellcome Trust, London, United Kingdom
School of Pharmacy, Curtin University of Technology, Bentley, Western Australia, Australia
University of Oslo, Oslo, Norway
IHCAR Div Global Health, Karolinska Institute, Stockholm, Sweden
IMANI Center for Policy & Education, Accra, Ghana
American Enterprise Institute, Washington, D.C., United States of America
Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
PN and NJW have scientific collaborations with the Enforcement Working Group of IMPACT, and NJW is co-chair of the WHO malaria treatment guidelines committee but none of the authors have shares in pharmaceutical companies or works as a part of IMPACT. NJW is a member of the PLoS Medicine Editorial Board. The Wellcome Trust had no role in the writing or decision to submit this viewpoint for publication, except for the involvement of CB as an author. BS is co-founder of MPedigree, which is a non-profit based in Ghana that advocates for the development of strategies to fight counterfeiting. All other authors have declared that no competing interests exist.
Wrote the first draft: PN. Contributed to the writing of the manuscript: PN AAA CB PP GD GT BS RB PJG NJW. ICMJE criteria for authorship read and met: PN AAA CB PP GD GT BS RB PJG NJW. Agree with the manuscript results and conclusions: PN AAA CB PP GD GT BS RB PJG NJW.